Takeda Pharmaceutical Company Limited
TKPHF
$39.20
$4.8113.99%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 331.11% | -112.92% | 40.77% | -3,229.30% | -78.22% |
| Total Depreciation and Amortization | 0.91% | -3.12% | 1.98% | -5.63% | -3.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | 20.80% | -- |
| Total Other Non-Cash Items | 38.95% | 174.32% | -65.67% | 264.17% | 314.10% |
| Change in Net Operating Assets | -143.85% | 131.23% | 54.65% | -95.29% | 151.74% |
| Cash from Operations | -3.75% | 35.68% | 36.51% | -22.32% | 153.62% |
| Capital Expenditure | 8.63% | 18.32% | 9.98% | -6.72% | 7.31% |
| Sale of Property, Plant, and Equipment | 85.33% | -100.00% | 76,516.98% | 1,455.56% | -97.10% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 148.57% | -93.38% | 974.83% | -45.49% | -- |
| Other Investing Activities | -163.95% | 72.78% | 77.87% | 148.28% | -143.99% |
| Cash from Investing | -96.79% | 35.43% | 77.14% | 68.82% | -48.59% |
| Total Debt Issued | -100.00% | -28.17% | -63.84% | 1,016.33% | -76.47% |
| Total Debt Repaid | 98.06% | 44.00% | -135.22% | -1,948.53% | -429.37% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -2,641.92% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.39% | 3.73% | -13.53% | -3.94% | -1.83% |
| Other Financing Activities | 15.42% | -27.00% | -167.35% | -10.78% | -20.11% |
| Cash from Financing | 70.97% | 89.03% | -173.30% | -404.89% | -549.44% |
| Foreign Exchange rate Adjustments | -2.93% | 132.24% | -115.26% | -189.47% | 810.87% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 92.80% | 518.65% | -110.91% | -162.67% | -1,089.38% |